Entrectinib (8) is a kinase inhibitor approved for ROS1-positive metastatic non-small cell lung cancer (NSCLC) and neurotrophic receptor tyrosine kinase gene fusion positive solid tumors. This evidence concerns the gene ROS1 and non-small cell lung carcinoma.